Nothing Special   »   [go: up one dir, main page]

DE69434332D1 - Thrombin mutanten - Google Patents

Thrombin mutanten

Info

Publication number
DE69434332D1
DE69434332D1 DE69434332T DE69434332T DE69434332D1 DE 69434332 D1 DE69434332 D1 DE 69434332D1 DE 69434332 T DE69434332 T DE 69434332T DE 69434332 T DE69434332 T DE 69434332T DE 69434332 D1 DE69434332 D1 DE 69434332D1
Authority
DE
Germany
Prior art keywords
nps
protein
useful
clotting
fibrinogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434332T
Other languages
English (en)
Other versions
DE69434332T2 (de
Inventor
Craig S Gibbs
Lawrence L K Leung
Manuel Tsiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of DE69434332D1 publication Critical patent/DE69434332D1/de
Publication of DE69434332T2 publication Critical patent/DE69434332T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69434332T 1993-11-12 1994-11-14 Thrombin mutanten Expired - Lifetime DE69434332T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15265793A 1993-11-12 1993-11-12
US152657 1993-11-12
US25803894A 1994-06-10 1994-06-10
US258038 1994-06-10
PCT/US1994/013104 WO1995013385A2 (en) 1993-11-12 1994-11-14 Thrombin mutants

Publications (2)

Publication Number Publication Date
DE69434332D1 true DE69434332D1 (de) 2005-05-19
DE69434332T2 DE69434332T2 (de) 2006-02-02

Family

ID=26849740

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69434332T Expired - Lifetime DE69434332T2 (de) 1993-11-12 1994-11-14 Thrombin mutanten

Country Status (9)

Country Link
US (1) US6110721A (de)
EP (1) EP0728210B1 (de)
JP (2) JPH09509045A (de)
CN (1) CN1103815C (de)
AT (1) ATE293168T1 (de)
AU (1) AU1096595A (de)
DE (1) DE69434332T2 (de)
ES (1) ES2240972T3 (de)
WO (1) WO1995013385A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT404357B (de) * 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
DE19781869T1 (de) * 1996-04-30 2000-03-16 Medtronic Inc Verfahren zur Herstellung eines autologen Fibrin-Blutstillungsmittels
WO2000062828A1 (en) * 1996-04-30 2000-10-26 Medtronic, Inc. Autologous fibrin sealant and method for making the same
US6270973B1 (en) * 1998-03-13 2001-08-07 Promega Corporation Multiplex method for nucleic acid detection
US20030069601A1 (en) * 1998-12-15 2003-04-10 Closys Corporation Clotting cascade initiating apparatus and methods of use
DE10012732A1 (de) * 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) * 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US6506365B1 (en) * 2000-09-25 2003-01-14 Baxter Aktiengesellschaft Fibrin/fibrinogen binding conjugate
EP1330544A4 (de) 2000-09-26 2005-04-06 Univ Duke Rna-aptamere und verfahren zu deren identifizierung
US6942880B1 (en) * 2001-04-09 2005-09-13 Medtronic, Inc. Autologous platelet gel having beneficial geometric shapes and methods of making the same
AU2002312059B2 (en) * 2001-05-25 2009-01-15 Duke University Modulators of pharmacological agents
WO2002100337A2 (en) * 2001-06-08 2002-12-19 Emory University Antithrombotic thrombin variants
CA2820537C (en) 2003-04-23 2015-10-20 Valeritas, Inc. Hydraulically actuated pump for fluid administration
CA2560247A1 (en) * 2004-03-19 2005-09-29 Chisso Corporation Thrombin derivative and pharmaceutical composition containing the same
PT1745062E (pt) * 2004-04-22 2014-07-11 Regado Biosciences Inc Moduladores melhorados de fatores de coagulação
JP2007159401A (ja) * 2004-05-07 2007-06-28 Precision System Science Co Ltd 改変タンパク質の作製方法
US9089636B2 (en) 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
US20100159512A1 (en) * 2006-03-06 2010-06-24 Kurt Osther Method for the preparation of recombinant human thrombin and fibrinogen
ES2566058T3 (es) 2006-03-30 2016-04-08 Valeritas, Inc. Dispositivo de suministro de fluidos de múltiples cartuchos
US9096839B2 (en) * 2006-04-26 2015-08-04 Arteriocyte Medical Systems, Inc. Compositions and methods of preparation thereof
JPWO2008059917A1 (ja) 2006-11-15 2010-03-04 チッソ株式会社 トロンビン変異体
US10231721B2 (en) 2010-06-24 2019-03-19 St. Croix Surgical Systems, Llc Failsafe percutaneous wound barrier
US20130309753A1 (en) * 2012-05-16 2013-11-21 Saint Louis University Recombinant auto-activating protease precursors
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
CN108135978A (zh) * 2015-10-08 2018-06-08 尼克塔治疗公司 IL-2Rβ选择性激动剂和长效IL-15激动剂的组合
WO2018089248A2 (en) * 2016-11-02 2018-05-17 Tucker Erik L E-we thrombin analog and fibrinolytic combination
MX2019013621A (es) 2017-05-15 2020-01-13 Nektar Therapeutics Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados.
CN111676208B (zh) * 2020-06-17 2021-11-02 江苏师范大学 一种定点突变改造的β-半乳糖苷酶及其构造方法
CN112062833A (zh) * 2020-10-09 2020-12-11 国药集团武汉血液制品有限公司 一种从血浆组分ⅳ沉淀中提取人血白蛋白的方法
CN115558015B (zh) * 2022-10-12 2024-01-19 生工生物工程（上海）股份有限公司 一种从gst融合蛋白酶切后的产物中纯化无gst标签的目的蛋白的方法和产品

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4303592A (en) * 1980-01-09 1981-12-01 Center For Blood Research, Inc. Amidinophenylmethylsulfonylfluoride
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) * 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5352664A (en) * 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
US5147638A (en) * 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
US5304482A (en) * 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
WO1991011519A1 (en) * 1990-01-26 1991-08-08 Immuno Aktiengesellschaft Recombinantly produced blood factors and process for the expression of said blood factors, as well as vaccinia virus recombinants used in said process
US5246850A (en) * 1990-07-31 1993-09-21 Genentech, Inc. DNA molecules encoding human tissue plasminogen activator variants with decreased clearance, vectors, and host cells
US5223408A (en) * 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
WO1993009807A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
ATE264913T1 (de) * 1992-02-05 2004-05-15 Paion Gmbh Protease-resistente analoge des thrombomodulin
CA2129660C (en) * 1992-06-03 2005-06-28 William F. Bennett Tissue plasminogen activator glycosylation variants with improved therapeutic properties

Also Published As

Publication number Publication date
EP0728210B1 (de) 2005-04-13
CN1139455A (zh) 1997-01-01
CN1103815C (zh) 2003-03-26
DE69434332T2 (de) 2006-02-02
WO1995013385A3 (en) 1996-02-01
AU1096595A (en) 1995-05-29
ATE293168T1 (de) 2005-04-15
JP2007312777A (ja) 2007-12-06
JPH09509045A (ja) 1997-09-16
EP0728210A1 (de) 1996-08-28
ES2240972T3 (es) 2005-10-16
US6110721A (en) 2000-08-29
WO1995013385A2 (en) 1995-05-18

Similar Documents

Publication Publication Date Title
ATE293168T1 (de) Thrombin mutanten
Hsieh et al. Differential regulation of macrophage inflammatory activation by fibrin and fibrinogen
Richardson et al. Chemotaxis for human monocytes by fibrinogen‐derived peptides
Mazzucco et al. Platelet‐rich plasma and platelet gel preparation using Plateltex®
DK1294414T3 (da) Præparat og fremgangsmåde til heling og regenerering af brusk og andre væv
DK2107109T3 (da) Rekombinant vaskulær endotelcelle-vækstfaktor D (VEGF-D)
NO944997L (no) Trombin-blodfraksjon for anvendelse ved en medisinsk fremgangsmåte
NL300009I1 (nl) Fusie-eiwitten met immuunglobulinedelen, hun bereiding en hun gebruik.
AU4159185A (en) Method of inhibiting binding of von willebrand factor to human platelets and inducing interaction of platelets with vessel walls
ATE195149T1 (de) Protein-antagonisten der blut-koagulation und ihre verwendung
US20040208786A1 (en) Autologous coagulant produced from anticoagulated whole blood
DK1124589T3 (da) Formulering af fibrin-vævsklæber og fremgangsmåde til fremstilling af denne
HU9201552D0 (en) Medical preparation for the neutralization of procoagulant activity cused by tumorous cells
Bajwa et al. Fibrinolytic and fibrinogen clotting enzymes present in the venoms of western diamondback rattlesnake, Crotalus atrox, eastern diamondback rattlesnake, Crotalus adamanteus, and southern Pacific rattlesnake, Crotalus viridis helleri
Seybold et al. Osteogenic differentiation of human mesenchymal stromal cells is promoted by a leukocytes containing fibrin matrix
BR9810242A (pt) Composições úteis como selante de fibrina
CA2019872A1 (en) Method and kit for determining the functional activity of protein s in human plasma
Gurevitz et al. Recombinant von Willebrand factor fragment AR545C inhibits platelet aggregation and enhances thrombolysis with rtPA in a rabbit thrombosis model
ATE175243T1 (de) Verwendung von prothrombinfragmenten
DE3685469D1 (de) Elastineprodukt, herstellungsverfahren und biologische anwendungen desselben, insbesondere als biomaterialien und kuenstliche traegerstoffe.
Perutelli et al. Abnormalities of plasma von Willebrand factor multimeric structure induced by extracorporeal circulation
Banerjee et al. Studies of actions of snake venoms on blood coagulation II. Electrophoretic analysis of venoms of Viperidae, Crotalidae, Elapidae and Hydrophidae
Becker Seminars in Thrombosis, Thrombolysis, and Vascular Biology: 6. Procoagulant States
Komp et al. The origin of cerebrospinal fluid procoagulant activity

Legal Events

Date Code Title Description
8364 No opposition during term of opposition